Table S VI.
Analysis of the evolution of the LP of the different generic Erlotinib medicines approved in Spain with respect to the innovative drug.
| Drug type & company | CIPM approval date | Marketing authorization date | CIPM LP (€/mg)* | Interval since 1st Gx approval by CIPM (years) | Price difference vs innovative price | Price difference vs 1st Gx approved by CIPM |
|---|---|---|---|---|---|---|
| Innovative (Roche) | 25/05/2007 | 19/09/2005 | 0.553 | NA | NA | NA |
| Generic 1 (Teva) | 25/04/2019 | 24/07/2018 | 0.319 | 0 | -42% | NA |
| Generic 2 (Hetero) | 29/02/2020 | 21/09/2018 | 0.319 | 0.8 | -42% | 0% |
| Generic 3 (Cipla) | 31/05/2020 | 09/01/2020 | 0.143 | 1.1 | -74% | -55% |
* In the case of the innovative drug, the authorized LP at the time of marketing of the first generic drug is indicated.